



NEWS RELEASE

Shareholder Notification

DURHAM, NC, and LIEGE, BELGIUM – December 10, 2010 – MDxHealth SA (NYSE Euronext: MDXH), reports that it received a notification dated December 8 that ING Investment Management Luxembourg SA's shareholding in the Company has decreased to below 3% of the total outstanding shares. The shareholding of ING Belgium NV/SA in the Company remains unchanged.

For further details on the transparency notifications received by the company, reference is made to our website www.mdxhealth.com.

About MDxHealth

MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The company's tests are based on patented gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research center such as Johns Hopkins University, Duke University, Lovelace Respiratory Research Institute, Eastern Virginia Medical School, Cleveland Clinic, Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono, Qiagen, and other industry leaders.

For more information:

Dr. Jan Groen, CEO
MDxHealth
+32 4 364 20 70

Hans Herklots
Capricorn One
+41 79 598 7149

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation